Talphera Advances Niyad™ Clinical Trial for Renal Replacement Therapy with Promising Enrollment Progress

Talphera Advances Clinical Trial for Niyad™ in Renal Replacement Therapy

Talphera, Inc. makes noteworthy progress in its pivotal NEPHRO CRRT clinical trial, which is currently evaluating the efficacy and safety of Niyad™, a nafamostat formulation, as an anticoagulant for adult patients undergoing renal replacement therapy. The company reports that approximately 25% of the trial's target enrollment has been achieved, with 17 patients recruited out of a planned 70. This milestone is particularly significant as it fulfills a prerequisite for closing the second tranche of a financing initiative announced in March 2025. The trial aims to address a critical need in intensive care settings where patients are at heightened risk of bleeding during renal treatments.

CEO Vince Angotti emphasizes the accelerated enrollment rates, crediting the recent addition of six new clinical sites that are projected to start enrolling patients in the third quarter. This strategic expansion has resulted in over 90% of the enrolled patients coming from these newly added sites. The trial is designed to be prospective and double-blinded, conducted across up to 14 hospital intensive care units throughout the United States. The primary endpoint focuses on mean post-filter activated clotting time during the first 24 hours of treatment with Niyad compared to a placebo, while secondary endpoints will assess various measures related to filter lifespan and overall dialysis effectiveness over a 72-hour period.

The NEPHRO CRRT trial also benefits from Niyad's designation as a Breakthrough Device by the FDA, underscoring its potential impact in the medical community. The successful execution of this study is critical for Talphera, not only in validating the therapeutic potential of Niyad but also in cementing the company’s commitment to advancing innovative treatments in medically supervised environments. With the anticipated completion of the study by the end of 2025, Talphera positions itself to make significant contributions to patient care in renal therapy.

In addition to the trial advancements, the overall strategy of expanding clinical sites reflects Talphera’s proactive approach to overcoming recruitment challenges often faced in clinical studies. By diversifying the locations and increasing the number of participating hospitals, the company aims to enhance the speed and efficiency of patient enrollment, which is vital for timely study completion.

The progress in the NEPHRO CRRT trial not only highlights Talphera's innovative capabilities but also reinforces the importance of enhancing patient outcomes in critical care settings. As the trial continues to enroll patients, the medical community watches closely, hopeful for the potential benefits that Niyad may offer to those requiring renal replacement therapy.